JAMP Pharma announces the creation of a new division BIOJAMP™ dedicated to biosimilars

Feb 1, 2022

JAMP Pharma announced the creation of a new division BIOJAMP™ dedicated to biosimilars.  The creation of this division was primarily made possible through JAMP’s exclusive agreement with Alvotech.  Through the creation of the BIOJAMP™ division, JAMP Pharma plans to establish itself as a Canadian leader in biosimilars.

Print Page Mail Article